CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-05 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −1,641 | $38.22 | $63K | 18,318 |
| 2023-01-05 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −689 | $39.10 | $27K | 17,629 |
| 2023-01-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −2,508 | $37.21 | $93K | 19,959 |
| 2023-01-04 | LEONARD JOHN M President and CEO | Sale | −6,673 | $37.21 | $248K | 766,825 |
| 2023-01-04 | Hicks Derek EVP, Chief Business Officer | Sale | −1,812 | $37.21 | $67K | 17,306 |
| 2023-01-04 | Lebwohl David EVP, Chief Medical Officer | Sale | −2,574 | $37.21 | $96K | 25,687 |
| 2023-01-04 | Goddard Glenn EVP, Chief Financial Officer | Sale | −2,427 | $37.21 | $90K | 15,404 |
| 2023-01-04 | Clark Eliana EVP, Chief Technical Officer | Sale | −1,692 | $37.21 | $63K | 14,473 |
| 2023-01-04 | BASTA JAMES EVP, General Counsel | Sale | −1,138 | $37.21 | $42K | 19,559 |
| 2023-01-03 | Clark Eliana EVP, Chief Technical Officer | Sale | −231 | $34.48 | $8K | 16,165 |
| 2023-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +3,500 | 22,467 | ||
| 2023-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise · Restricted Stock Unit | −3,500 | 7,000 | ||
| 2023-01-01 | LEONARD JOHN M President and CEO | Option exercise | +7,848 | 773,498 | ||
| 2023-01-01 | LEONARD JOHN M President and CEO | Option exercise · Restricted Stock Unit | −7,848 | 15,698 | ||
| 2023-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,187 | 28,261 | ||
| 2023-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,187 | 6,376 | ||
| 2023-01-01 | Goddard Glenn EVP, Chief Financial Officer | Option exercise | +3,062 | 17,831 | ||
| 2023-01-01 | Goddard Glenn EVP, Chief Financial Officer | Option exercise · Restricted Stock Unit | −3,062 | 6,126 | ||
| 2022-07-01 | Clark Eliana EVP, Chief Technical Officer | Sale | −105 | $51.74 | $5K | 16,165 |
| 2022-06-14 | Verwiel Frank Director | Grant or award | +5,197 | 7,291 |
Page 11 of 40 · 783 trades